

February 11, 2021

The Honorable Tammy Baldwin  
U.S. Senate  
709 Hart Senate Office Building  
Washington, DC 20510

Dear Senator Baldwin:

The undersigned organizations, institutions, and companies representing a broad range of scientific, public health, and clinical professionals, write to express our support for S. 236, the Tracking COVID-19 Variants Act. Significantly boosting U.S. genetic surveillance and viral sequencing is key to responding to the evolving challenges of the COVID-19 pandemic. As new SARS-CoV-2 variants emerge, we need this sequencing capacity to identify, track, and mitigate the impact of these new strains, including conducting epidemiologic investigations to determine the significance of new variants on human health.

We are especially pleased that the bill authorizes up to \$2 billion in emergency supplemental funding for the Advanced Molecular Detection (AMD) program at the Centers for Disease Control and Prevention (CDC) to bolster and accelerate its ongoing vital work to conduct national sequence-based viral surveillance and integrate genomics and genomic epidemiology. This work has been conducted in part through an innovative public-private partnership, the Sequencing for Public Health Emergency Response, Epidemiology, and Surveillance (SPHERES) Consortium, which includes dozens of members from all segments of the clinical and research laboratory community.

Currently, the U.S. lags far behind other countries in its ability to sequence viral samples. This funding will bring our nation up from a sequencing level of 0.3 percent ([43<sup>rd</sup> in the world](#)) to a level that allows for sequencing an adequate sample to estimate variant circulation nationally. With much-needed supplemental funding through CDC's AMD program into the combined resources of public health, academic, and clinical laboratories, as well as research institutions and private sector entities, the U.S. will rapidly expand sequencing to provide a complete picture of the circulating virus, its patterns of transmission, and how it is evolving as we begin immunizing the population.

Since 2014, the AMD program has employed next generation sequencing (NGS) to bring the concept of precision medicine to bear for "precision public health." AMD has given us new tools to detect disease faster, identify outbreaks sooner, and protect people from emerging and evolving disease threats. The importance of the AMD program and its work to our response to SARS-CoV-2 cannot be overstated, and without the resources authorized in this legislation, we will not be able to reach the level of surveillance needed to protect Americans from the ongoing threat of SARS-CoV-2.

We thank you for introducing this important legislation. We urge its swift enactment by Congress, and we look forward to working with you and your colleagues to meet the moment through more robust genetic surveillance by ensuring CDC's AMD program has the resources it needs to carry out this critical work.

Sincerely,

AdvaMedDx  
American Association of Bioanalysts  
American Clinical Laboratory Association  
American Institute of Biological Sciences  
American Lung Association  
American Medical Technologists  
American Psychological Association  
American Society for Clinical Pathology  
American Society for Microbiology  
American Society for Virology  
American Society of Tropical Medicine and Hygiene  
Association for Molecular Pathology  
Association of American Medical Colleges  
Association of Pathology Chairs  
Association of Professionals in Infection Control and Epidemiology  
Association of Public Health Laboratories  
Association of Schools and Programs of Public Health  
Biophysical Society  
California Life Sciences Association  
Council of State and Territorial Epidemiologists  
Emory University  
Exact Sciences Laboratories  
GenMark Diagnostics  
Ginkgo Bioworks  
Helix  
Illumina  
Infectious Diseases Society of America  
Institute of Environmental Science and Research Limited  
Invitae  
Laboratory Corporation of America Holdings  
National Independent Laboratory Association  
Psomagen  
Shenandoah University  
Society for Healthcare Epidemiology of America  
Society for Public Health Education  
Society of Infectious Diseases Pharmacists  
The Gerontological Society of America  
The Jackson Laboratory  
Thermo Fisher Scientific  
Trust for America's Health  
University of California Health System  
University of Minnesota  
University of Wisconsin-Madison  
University of Wisconsin-Madison School of Medicine and Public Health

February 11, 2021

The Honorable Ami Bera  
U.S. House of Representatives  
172 Cannon House Office Building  
Washington, DC 20515

The Honorable Scott Peters  
U.S. House of Representatives  
1201 Longworth House Office Building  
Washington, DC 20515

Dear Representatives Bera and Peters:

The undersigned organizations, institutions, and companies representing a broad range of scientific, public health, and clinical professionals, write to express our support for H R. 791, the Tracking COVID-19 Variants Act. Significantly boosting U.S. genetic surveillance and viral sequencing is key to responding to the evolving challenges of the COVID-19 pandemic. As new SARS-CoV-2 variants emerge, we need this sequencing capacity to identify, track, and mitigate the impact of these new strains, including conducting epidemiologic investigations to determine the significance of new variants on human health.

We are especially pleased that the bill authorizes up to \$2 billion in emergency supplemental funding for the Advanced Molecular Detection (AMD) program at the Centers for Disease Control and Prevention (CDC) to bolster and accelerate its ongoing vital work to conduct national sequence-based viral surveillance and integrate genomics and genomic epidemiology. This work has been conducted in part through an innovative public-private partnership, the Sequencing for Public Health Emergency Response, Epidemiology, and Surveillance (SPHERES) Consortium, which includes dozens of members from all segments of the clinical and research laboratory community.

Currently, the U.S. lags far behind other countries in its ability to sequence viral samples. This funding will bring our nation up from a sequencing level of 0.3 percent ([43<sup>rd</sup> in the world](#)) to a level that allows for sequencing an adequate sample to estimate variant circulation nationally. With much-needed supplemental funding through CDC's AMD program into the combined resources of public health, academic, and clinical laboratories, as well as research institutions and private sector entities, the U.S. will rapidly expand sequencing to provide a complete picture of the circulating virus, its patterns of transmission, and how it is evolving as we begin immunizing the population.

Since 2014, the AMD program has employed next generation sequencing (NGS) to bring the concept of precision medicine to bear for "precision public health." AMD has given us new tools to detect disease faster, identify outbreaks sooner, and protect people from emerging and evolving disease threats. The importance of the AMD program and its work to our response to SARS-CoV-2 cannot be overstated, and without the resources authorized in this legislation, we will not be able to reach the level of surveillance needed to protect Americans from the ongoing threat of SARS-CoV-2.

We thank you for introducing this important legislation. We urge its swift enactment by Congress, and we look forward to working with you and your colleagues to meet the moment through more robust genetic surveillance by ensuring CDC's AMD program has the resources it needs to carry out this critical work.

Sincerely,

AdvaMedDx  
American Association of Bioanalysts  
American Clinical Laboratory Association  
American Institute of Biological Sciences  
American Lung Association  
American Medical Technologists  
American Psychological Association  
American Society for Clinical Pathology  
American Society for Microbiology  
American Society for Virology  
American Society of Tropical Medicine and Hygiene  
Association for Molecular Pathology  
Association of American Medical Colleges  
Association of Pathology Chairs  
Association of Professionals in Infection Control and Epidemiology  
Association of Public Health Laboratories  
Association of Schools and Programs of Public Health  
Biophysical Society  
California Life Sciences Association  
Clear Labs  
Council of State and Territorial Epidemiologists  
Emory University  
Exact Sciences Laboratories  
GenMark Diagnostics  
Ginkgo Bioworks  
Helix  
Illumina  
Infectious Diseases Society of America  
Institute of Environmental Science and Research Limited  
Invitae  
Laboratory Corporation of America Holdings  
National Independent Laboratory Association  
Psomagen  
Shenandoah University  
Society for Healthcare Epidemiology of America  
Society for Public Health Education  
Society of Infectious Diseases Pharmacists  
The Gerontological Society of America  
The Jackson Laboratory  
Thermo Fisher Scientific  
Trust for America's Health  
University of California Health System  
University of Minnesota  
University of Wisconsin-Madison  
University of Wisconsin-Madison School of Medicine and Public Health

